United Therapeutics price target raised to $660 from $600 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on United Therapeutics (UTHR) to $660 from $600 and keeps a Buy rating on the shares as the firm argues that the data from the TETON-1 study strengthens the case for expanding Tyvaso in idiopathic pulmonary fibrosis. TETON-1 surpassed TETON-2 and “beat best-case expectations,” says the analyst, who believes Tyvaso is now positioned to become part of the IPF standard of care.